Harvard Management Company’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Harvard Management Company’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-400,000	Closed	-$724K	–	34
2023 Q2	$724K	Hold	400,000	–	–	0.07%	29
2023 Q1	$528K	Hold	400,000	–	–	0.06%	45
2022 Q4	$676K	Hold	400,000	–	–	0.08%	42
2022 Q3	$740K	Hold	400,000	–	–	0.09%	45
2022 Q2	$1.23M	Hold	400,000	–	–	0.14%	38
2022 Q1	$2.89M	Hold	400,000	–	–	0.29%	35
2021 Q4	$6.55M	Hold	400,000	–	–	0.61%	36
2021 Q3	$3.98M	Hold	400,000	–	–	0.23%	31
2021 Q2	$4M	Hold	400,000	–	–	0.23%	29
2021 Q1	$3.98M	Buy	+400,000	New	+$4.14M	0.22%	32

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Harvard Management Company's PRDS Position: Q3 2023 in Review

Harvard Management Company sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 400,000 shares — an estimated $724K sold.

Harvard Management Company first reported a position in PRDS in Q1 2021 and held it in 10 quarters. The position peaked at $6.55M in Q4 2021. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Harvard Management Company reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 400,000 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $724K.
Harvard Management Company first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Harvard Management Company's Pardes Biosciences, Inc. Common Stock position peaked at $6.55M in Q4 2021.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.